Do you want to read an article? Please log in or register.
Mapping Real-world Rebiopsy Events to Treatment Trajectories in EGFR/ALK/ROS1-Driven Non-small-cell Lung Cancer: Insights from the AURORA Cohort
Lung Cancer
Related content
COMMENTED
Lung Cancer
Real-World Treatment Patterns and Survival in Patients with ROS1-Positive Advanced Non-Small Cell Lung Cancer in Canada and Europe
★ 1
Recommended by
Dr. med. Martin Frey, Faculty Member
★ 3
Recommended and commented by
Dr Marcus Hesse, Faculty Member
Curr Oncol
Cheung WY, Lee A, Bote de Cabo H, Burdenski K, Christopoulos P, Pinto-Correia B, Deshayes S, Girard N, Hindocha P, Madden Á, Mella M, Moreira J, Rizzi S, Abreu DR, Soares M, Thomas J, Han M, Calvet CY, Emanuel G, Glassberg MB, Jacobs H, Rault C, Yuan Y, Chouaid C
doi: 10.3390/curroncol33030152
Lung Cancer
Aumolertinib Versus Osimertinib as First-Line Treatment for EGFR-Mutant Non-Small Cell Lung Cancer: A Retrospective Real-World Multicenter Study
Int J Cancer
Wang J, Qi P, Li J, Wang N, Fu C, Liu L, Li S, Li X, Hou X, Qiao H
doi: 10.1002/ijc.70617
RECOMMENDED
Lung Cancer
Real-world incidence, prevalence, and clinical impact of brain metastases in patients with ALK-positive metastatic non-small cell lung cancer treated with first-line ALK tyrosine kinase inhibitors
★ 1
Recommended by
Dr. med. Martin Frey, Faculty Member
★ 2
Recommended by
Dr Marcus Hesse, Faculty Member
Lung Cancer
Liu G, Abrahami D, Ramachandran P, Messina R, Rifi N, Yang H, Chai X, Li B, Ramaswamy K, Iyengar P, Pennell NA, Shaw AT
doi: 10.1016/j.lungcan.2025.108858
Lung Cancer
Comparative effectiveness of first-line targeted therapies in ALK-positive non-small cell lung cancer: real-world evidence of tyrosine kinase inhibitors
Lung Cancer
Mudumba R, Liu X, Jin S, Davis IJ, Baid D, Romley JA, Nieva JJ
doi: 10.1016/j.lungcan.2026.109451
Lung Cancer
Real-World Effectiveness of Second-Line Therapies in Advanced Non-Small Cell Lung Cancer: Insights From Propensity-Weighted Comparative Analyses of Longitudinal EHR Data
Clin Lung Cancer
Hettinger GCN, Long Q, Parikh RB
doi: 10.1016/j.cllc.2025.09.010
Lung Cancer
Treatment Sequencing and Immunotherapy Rechallenge in Advanced Non-Small-Cell Lung Cancer: Final 24-Month Real-World Results from the French LIST Study
Oncol Ther
Godbert B, Gobbini E, Khalife Y, Decroisette C, Brellier F, Lena H, Fleuriet A, Zysman M, Egenod T, Girard N
doi: 10.1007/s40487-026-00437-8
Lung Cancer
Treatment and outcomes of limited stage small cell lung cancer in the Canadian small cell lung cancer database (CASCADE)
Lung Cancer
Phillips WJ, Zhan LJ, Chowdhury D, Gill J, Sun A, Rittberg R, Cohen V, Gibson AJW, Yan M, Liwski D, Surapaneni S, D'Amours MF, Yu FPS, Kim Y, Qadeer RA, Dawe DE, Agulnik J, Navani V, Fung AS, Snow S, Kuruvilla S, Ho C, Lok BH, Liu G, Wheatley-Price P, Moore S
doi: 10.1016/j.lungcan.2025.108840
RECOMMENDED
Lung Cancer
Impact of First-Line Maintenance Immunotherapy With or Without Pemetrexed for Non-Squamous Advanced/Metastatic Non-Small Cell Lung Cancer Lacking Targetable Mutations: A Real-World Analysis in England
★ 1
Recommended by
Dr. med. Martin Frey, Faculty Member
Clin Lung Cancer
Gomes F, Gilding N, Tan V, Christoforou K, Rule J, Aziez A, Januszewski A, Minchom A
doi: 10.1016/j.cllc.2025.12.007
Lung Cancer
Real-World Comparative Effectiveness of First-Line Dabrafenib Plus Trametinib Versus Immunochemotherapy in Patients with Advanced BRAF V600-Mutant Non-Small-Cell Lung Cancer: A Retrospective Cohort Study
J Clin Med
Yue H, Zhou Q, Wang S, Li S, Li J, La H, Meng S
doi: 10.3390/jcm15176749